Can ramucirumab, irinotecan, calcium folinate (leucovorin), and fluorouracil (5‑fluorouracil) cause chest pain?

Can These Agents Cause Chest Pain?

Yes, fluorouracil (5-FU) definitively causes chest pain with an incidence of 1-68%, and this is a well-established cardiotoxic effect that requires immediate drug discontinuation when it occurs 1, 2. The other agents in your question have different risk profiles.

Fluorouracil (5-FU) - HIGH RISK

5-FU is the primary culprit for chest pain among these agents. The mechanism is coronary vasospasm, with cardiac events typically occurring within 5 days of first administration 2. The FDA label confirms angina pectoris and myocardial ischemia as documented adverse events 3.

Key Clinical Features:

• Incidence: 1-68% depending on the study, with most recent data showing 3-5% 4, 5
• Timing: Usually within 3 days (range 2-6 days) of administration 5
• Presentation: Angina-like chest pain, ECG ischemic changes in 68% of symptomatic patients 2
• Serious outcomes: Can progress to STEMI, cardiac arrest, or sudden death (0.4-0.5% incidence) 4

Risk Factors to Identify:

• Pre-existing coronary artery disease (15.1% cardiotoxicity rate vs 1.5% without cardiac history) 5
• High-dose 5-FU (>800 mg/m²) 2
• Continuous infusion (higher risk than bolus) 2
• Prior mediastinal radiation 2

Management Algorithm:

1. If chest pain develops during 5-FU:

   • Immediately discontinue the drug 1
   • Obtain serial ECGs 1
   • Institute anti-anginal therapy (nitrates, calcium channel blockers) 1

2. For rechallenge (only if absolutely necessary):

   • Switch from infusion to bolus dosing 6, 7
   • Pretreat with diltiazem or isosorbide dinitrate 6, 7
   • Use continuous telemetry monitoring 7
   • However, an alternative regimen without 5-FU is the better option 1

3. Prophylaxis in high-risk patients:

   • Consider preemptive coronary vasodilators (nitrates, calcium channel blockers) 1
   • Perform ischemic workup before starting therapy 1

Critical pitfall: Nitrates administered therapeutically after symptoms develop have shown no significant effect 5. Prophylactic use is more effective.

Calcium Folinate (Leucovorin) - LOW RISK

Leucovorin itself does not cause chest pain. When combined with 5-FU, the cardiotoxicity rate (3%) is not significantly higher than 5-FU alone 5. The chest pain risk comes from the 5-FU component, not the leucovorin.

Irinotecan - MINIMAL DIRECT CARDIAC RISK

The FDA label for irinotecan lists thromboembolic events (9.3-11.4%) including myocardial infarction and myocardial ischemia 3, but these are thrombotic complications, not direct cardiotoxicity like vasospasm. Chest pain is not a characteristic adverse effect of irinotecan monotherapy.

Documented cardiovascular events:

• Thromboembolic complications (arterial thrombosis, MI, pulmonary embolus) 3
• These occur as part of the prothrombotic state from chemotherapy, not vasospasm

Ramucirumab - MINIMAL DIRECT CARDIAC RISK

Ramucirumab is not specifically associated with chest pain or coronary vasospasm. As a VEGF receptor-2 antagonist, its cardiovascular concerns are:

• Arterial thromboembolic events (general risk with anti-angiogenic agents)
• Hypertension (8% grade 3/4) 8

The combination regimen FOLFIRI + ramucirumab shows the same cardiotoxicity profile as FOLFIRI alone, with the chest pain risk attributable to the fluorouracil component 9, 8.

Bottom Line for Clinical Practice

Monitor specifically for 5-FU-induced chest pain in the first week of treatment. If it occurs:

1. Stop 5-FU immediately
2. Obtain ECG
3. Start anti-anginal therapy
4. Do not rechallenge unless absolutely necessary, and only with prophylactic vasodilators and bolus dosing

The other three agents (ramucirumab, irinotecan, leucovorin) do not independently cause the vasospastic chest pain syndrome characteristic of fluoropyrimidines 1, 2, 10, 4.